July 13, 2018 10:22 AM EDT
News Briefing

Tai­ho kicks off $130M Ar­cus deal with drug op­tion; J&J al­lies with Mer­ck KGaA to take di­a­betes drug to Chi­na

Brittany Meiling

→ Japan’s Tai­ho Phar­ma has de­cid­ed to go for an op­tion to de­vel­op and com­mer­cial­ize an adeno­sine re­cep­tor an­tag­o­nist pro­gram from Ar­cus Bio­sciences $RCUS, trig­ger­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times